null

The phrase "DNA of cancer cells" refers to the entire genome within malignant cells, comprising all genetic and epigenetic alterations accumulated during carcinogenesis. These changes, including mutations in oncogenes or tumor suppressor genes, chromosomal rearrangements, and abnormal methylation, drive uncontrolled proliferation and survival. Cancer therapies may target DNA directly (e.g., alkylating agents) or exploit specific features of tumor DNA (e.g., synthetic lethality in homologous recombination-deficient cells via PARP inhibitors). Advances in next-generation sequencing and ctDNA analysis enable precision oncology, allowing clinicians to select drugs based on actionable mutations or other DNA-based biomarkers and to monitor response or resistance during treatment. "DNA of cancer cells" is not a proper molecular target name; instead, therapeutic focus is on specific gene mutations, repair pathways, or epigenetic states identifiable within the cancer genome.

Other names

Cancer cell genomic DNATumor DNACancer genome

Inhibition of DNA repair pathways (synthetic lethality via PARP inhibition in BRCA-mutated cells); Disruption of DNA replication or maintenance (topoisomerase inhibition, platinum DNA crosslinking); Epigenetic modulation (inhibition of DNA methylation)